MONTREAL and SAN FRANCISCO, CA -- (MARKET WIRE) -- May 22, 2007 -- TOPIGEN Pharmaceuticals, Inc., a clinical stage biopharmaceutical company specializing in respiratory disorders, today announced that it presented new clinical data concerning its lead product, TPI ASM8 for asthma, during the American Thoracic Society (ATS) Annual Meeting, held in San Francisco at the Moscone Convention Center (May 18 - 23, 2007). With more than 13,000 members, the ATS is a leading medical association dedicated to advancing lung, critical care and sleep medicine.
